These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18355979)

  • 1. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.
    Caudell JJ; Sawrie SM; Spencer SA; Desmond RA; Carroll WR; Peters GE; Nabell LM; Meredith RF; Bonner JA
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):676-81. PubMed ID: 18355979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distant metastases in head-and-neck squamous cell carcinoma treated with intensity-modulated radiotherapy.
    Yao M; Lu M; Savvides PS; Rezaee R; Zender CA; Lavertu P; Buatti JM; Machtay M
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):684-9. PubMed ID: 22169673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer.
    Watkins JM; Zauls AJ; Wahlquist AH; Shirai K; Garrett-Mayer E; Gillespie MB; Day TA; Sharma AK
    Laryngoscope; 2010 Feb; 120(2):236-42. PubMed ID: 19950378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
    Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
    Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment prognostic factors influencing distant metastasis-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy.
    Jeremić B; Miličić B
    Am J Clin Oncol; 2009 Oct; 32(5):483-7. PubMed ID: 19506455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis.
    Siddiqui F; Pajak TF; Watkins-Bruner D; Konski AA; Coyne JC; Gwede CK; Garden AS; Spencer SA; Jones C; Movsas B
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):353-60. PubMed ID: 17889449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer.
    Malone JP; Stephens JA; Grecula JC; Rhoades CA; Ghaheri BA; Schuller DE
    Head Neck; 2004 Jul; 26(7):561-72. PubMed ID: 15229898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.
    Chua DT; Wei WI; Sham JS; Cheng AC; Au G
    Head Neck; 2003 Jul; 25(7):585-94. PubMed ID: 12808662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy.
    Fang LC; Komaki R; Allen P; Guerrero T; Mohan R; Cox JD
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):108-16. PubMed ID: 16904517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck.
    Pradier O; Christiansen H; Schmidberger H; Martin A; Jäckel MC; Steiner W; Ambrosch P; Kahler E; Hess CF
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1368-77. PubMed ID: 16169679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
    Sher DJ; Haddad RI; Norris CM; Posner MR; Wirth LJ; Goguen LA; Annino D; Balboni T; Allen A; Tishler RB
    Cancer; 2010 Oct; 116(20):4761-8. PubMed ID: 20572036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review.
    Lawenda BD; Arnold MG; Tokarz VA; Silverstein JR; Busse PM; McIntyre JF; Deschler DG; Baldini EH; Kachnic LA
    Ear Nose Throat J; 2008 Nov; 87(11):634-43. PubMed ID: 19006065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
    Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
    Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution.
    Adelstein DJ; Saxton JP; Rybicki LA; Esclamado RM; Wood BG; Strome M; Lavertu P; Lorenz RR; Carroll MA
    J Clin Oncol; 2006 Mar; 24(7):1064-71. PubMed ID: 16505425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.